scar size, which was sustained for up to five years; however, there was a lack of sufficient evidence to evaluate any improvements in longterm survival rates 13 . As the Cochrane study pooled all study results without considering other study parameters, the task force of the European Society of Cardiology for Stem Cells and Cardiac Repair recently received funding from the EU to address the broader question of patient benefit through a large-scale trial (called BAMI) with more than 3,000 patients using standardized treatment procedures. This trial will attempt to determine whether stem cell therapy is truly effective in the treatment of heart attacks and, more important, whether it improves long-term survival of patients.
We propose that, whereas clinical investigation in cardiac cell therapy must push forwardgiven the evidence of safety and potential clinical benefit-it is time to re-examine the fundamentals of cardiac regeneration and address crucial questions at the bench. Although some investigators may believe these questions are already answered, there is controversy and confusion in the field that should be addressed by different groups using multiple independent techniques.
Is there adult cardiac stem cell activity in the mammalian heart before or after damage, and can we measure this with precision? Is cardiac cell therapy with putative progenitor or stem cells causing true regeneration in humans, as in zebrafish and neonatal mice [14] [15] [16] , where regeneration is definitively established through cardiomyocyte division? Is cardiac cell therapy simply a means of delivery of paracrine factors, or does it lead to long-term integration of functional and electrically stable cardiomyocytes derived from these cells? And, perhaps most important, if other models can clearly regenerate myocardium, why can't adult mammals do this? Researchers do not yet even agree on whether there is a cardiac progenitor stem cell in the heart. Lineage-tracing studies should reproducibly show that any putative progenitor cell has the ability to differentiate to cardiomyocytes that integrate electromechanically long term in the heart in vivo. Deletion of the putative cardiac progenitor should also result in impairment of any endogenous heart repair mechanism and failure to find increased numbers of new cardiomyocytes derived from any recruited progenitors in the region of damage.
No matter what the results of clinical cardiac cell therapy trials, investigators in the field must answer these questions rigorously, preferably before larger randomized clinical trials are undertaken. Subjecting control individuals to a cardiac biopsy to collect putative cardiac progenitors is considerably more invasive than bone marrow collection. In addition, if positive results from early clinical studies are not reproduced by more definitive, larger trials, researchers will need to understand what has gone wrong. If the larger trials show improved cardiac function, which is our sincere hope, clinicians will need these answers to improve the cell therapy approach to treat more patients with myocardial infarction and reduce their chances of developing later heart failure.
For patients in the next decade who might benefit from cardiac cell therapy, researchers do not need to understand all of the fundamentals of cardiac regeneration as long as the therapies are safe. Throughout history, people have benefited from therapies despite the lack of complete or correct understanding of mechanism. However, for the long-term goal of achieving definitive cardiac regeneration, it is time to state explicitly that the scientific community does not agree on the answers to the most fundamental scientific questions regarding stem cell therapy for cardiac repair. Comparative studies of different types of stem cells in identical animal models of myocardial infarction in which cell numbers and types, means and timing of delivery and functional readouts are carefully controlled are essential to move the field forward in a rational way. As mouse and zebrafish hearts differ from those of humans, multiple organisms, including humans whenever possible, should be used to address fundamental biological and functional questions.
The heart is an organ that relies not only on mechanical performance but also on remarkable long-term electrical stability, and the risks of cardiac therapies are obvious. As clinical studies in the past century revealed, simply getting the heart to beat stronger was not a wise strategy, as many therapies that improved cardiac function also acutely increased the risk of sudden death. Investigators clearly need to worry about further understanding the basic biology of cardiac regeneration; in the long run, they cannot afford to be wrong.
Nearly one million Americans suffer a myocardial infarction each year, many of whom progress to heart failure, the single most common hospital discharge diagnosis in those over age 65 (ref. 1). The adult human heart has a limited regenerative response to injury such that the loss or dysfunction of cardiomyocytes results in reduced pump function, often culminating in heart failure, life-threatening arrhythmias and sudden death. Numerous clinical trials over the past decade have introduced a variety of autologous stem and progenitor cell types into failing human hearts as a strategy for regenerating new myocardium, but exogenous stem cells seem to give rise to few if any new muscle cells, bringing into question the biological basis for the limited functional improvement. Thus, there is still a dire need for innovative strategies for heart regeneration and repair.
A series of recent studies in rodents has reported the ability of exogenous transcription factors and miRNAs to reprogram cardiac fibroblasts into cardiomyocytes [2] [3] [4] [5] [6] , resulting in dramatic improvement of cardiac contractility after myocardial infarction 2, 3, 6 . Much work remains to optimize such reprogramming methods and to define the mechanistic basis for functional improvement in this setting, but this initial evidence suggests a potentially transformative new approach for heart repair.
Whereas skeletal and smooth muscle cells can be generated from fibroblasts by ectopic expression of single transcription factors 7, 8 , the cardiac muscle phenotype has proven more elusive, as no single factor has been shown to be capable of generating cardiomyocytes from fibroblasts. An important step toward possible therapeutic generation of cardiomyocytes was provided by Ieda et al. 9 , who showed that three transcription factors-Gata4, Mef2c and Tbx5 (together referred to as GMT)-could activate cardiac gene expression in cultured mouse fibroblasts with a low efficiency of between 5 and 15%. Activation of cardiac genes by these factors seems to require precise levels of expression of the factors. Inclusion of a fourth factor, Hand2, in the GMT cocktail substantially increases reprogramming efficiency 2 . Several cardiac miRNAs have also been reported to activate cardiac gene expression in fibroblasts with low efficiency 4 . Because cardiac transcription factors and miRNAs function within complex regulatory networks involving feedforward and autoregulatory interactions, it is likely that multiple combinations of these cardiac regulators may initiate the cardiac phenotype.
Reprogramming by cardiac transcription factors and miRNAs seems to involve direct conversion of fibroblasts toward a cardiomyocyte-like fate without transition through a stem cell intermediate. This approach therefore differs from reprogramming methods that involve the generation of induced pluripotent stem cells and subsequent commitment to the cardiac lineage. Direct cardiac reprogramming of fibroblasts also circumvents potential teratogenicity and immunogenicity of induced pluripotent stem cells.
Induced cardiac-like myocytes (iCLMs) seem to be relatively immature, and only a very low fraction show action potentials and strong contractility, well-developed sarcomeres, and binucleation, characteristics of adult cardiomyocytes. Thus, maturation to adult cardiac phenotypes may require prolonged periods in culture or additional factors not yet identified. Initial efforts to reprogram human fibroblasts to a cardiac fate have recently found a set of at least five factors different from the factor combination in mouse fibroblasts that can activate cardiac gene expression in adult human cardiac and dermal fibroblasts and in neonatal human foreskin fibroblasts 10 . Cardiac reprogramming of human fibroblasts is slower and less efficient than in mouse fibroblasts, perhaps reflecting stable epigenetic events that need to be overcome.
Nearly half of the cells in the heart are fibroblasts, and their activation during heart disease leads to fibrosis, which impedes contractility and contributes to conduction abnormalities. Thus, targeting activated cardiac fibroblasts after injury to induce heart repair is particularly attractive (Fig. 1) . Retroviruses, which infect only proliferating cells, were used to introduce GMT and GHMT into fibroblasts in the infarct zone of mice after myocardial infarction 2, 3, 5 . Lineagetracing studies with fibroblast markers indicated that newly generated iCLMs were derived from fibroblasts.
There are a few aspects of these studies that warrant consideration. First, the reprogramming efficiency in vivo seems to be higher compared to in vitro, suggesting that the milieu of the intact heart may favor reprogramming in ways that cannot be reproduced in culture. Second, introduction of reprogramming factors results in dramatic functional improvement after myocardial infarction 2, 3 , indicating that, at least in mice, the impact of cardiac reprogramming exceeds the relatively modest and transient effects observed with autologous stem cell transplantation. Finally, the extent of functional improvement after in vivo reprogramming is greater than expected, given the relatively modest number of mature cardiomyocytes generated. This may suggest that reprogramming factors enhance cardiac function through mechanisms beyond simply reprogramming of fibroblasts toward a cardiomyocyte cell fate, perhaps also promoting neoangiogenesis, preventing cardiomyocyte death and/or inhibiting fibroblast proliferation.
Although these initial studies point to a potentially promising new approach for heart repair, numerous technical and biological hurdles remain to be overcome. The efficiency of the reprogramming process remains relatively low, and reprogrammed cells show a spectrum of intermediate phenotypes, reflecting incomplete conversion to a mature cardiac phenotype. The latter issue is of concern, given the propensity of arrhythmias to arise from zones of cardiomyocyte heterogeneity 11 . The longterm stability and integration of reprogrammed cardiomyocytes with native cardiomyocytes also remains to be shown. Further optimization of reprogramming of human fibroblasts and demonstration of the therapeutic efficacy and safety of this approach in large animals is needed.
Cells from the cardiac conduction system and vasculature are also lost after cardiac injury, and full restoration of cardiac function after injury will therefore require recreation of multiple cell types. Smooth muscle, endothelial and angioblast-like progenitor cells have been efficiently generated by reprogramming 8, 12, 13 and inclusion of a vascular endothelial growth factor-expressing virus with GMT enhances functional recovery of mice after myocardial infarction, possibly through neovascularization of the injured myocardium 6 . In addition, forced expression of Tbx3, activated Notch or Tbx18 in working cardiomyocytes is sufficient to generate conduction system cells in vitro [14] [15] [16] and in vivo 16 . Reprogramming experiments in rodents requires open chest surgery to directly inject viruses into the infarct zone; in humans, direct delivery of reprogramming factors during coronary artery bypass graft surgery could be a starting point. Given the potential for teratogenic viral insertions in the genome, as well as other complications associated with viral delivery, it will be important to develop nonintegrative methods for safe clinical application. Replacing cardiogenic transcription factors with small molecules or synthetic oligonucleotides with cardiogenic activity has long-term therapeutic possibilities; their combination with catheter-based delivery during a percutaneous coronary artery intervention after myocardial infarction could also reach widespread and effective use for intervention after heart attack.
Whereas studies thus far have been limited to the reprogramming of fibroblasts to cardiomyocytes within the infarct zone of hearts after myocardial infarction, it will be of interest to determine whether this approach can also be applied to other forms of acquired and inherited forms of heart disease associated with loss or dysfunction of cardiomyocytes. As most heart diseases are associated with an increase in cardiac fibrosis, this approach may extend beyond post-myocardial infarction therapy. Given our desperate need for entirely new heart repair strategies, further studies are warranted to resolve the current challenges facing in vivo reprogramming approaches. Cellular reprogramming, perhaps in combination with biological scaffolds or other bioengineering strategies, has the potential to provide an alternative or complementary heart repair strategy to cell transplantation-based approaches, which have been in clinical trials for nearly a decade.
